Psoriasis

The current dermatology pipeline includes a wide range of medication classes, from Janus kinase (JAK) inhibitors to tumor necrosis factor inhibitors, to phototherapeutics

Experts discuss the landscape of topical drugs for plaque psoriasis (PP) and key factors in treatment options.

Tj Chao, MPAS, and Lauren Miller, MPAS, highlight treatment efficacy considerations for plaque psoriasis (PP).

Experts in dermatology review a patient case of a 48-year-old man with plaque psoriasis who is having trouble with topical therapy.

Dermatology experts discuss a patient case concerning a 60-year-old woman with chronic intertriginous psoriasis who is taking a biologic drug for inflammatory bowel disease.

Del Rosso and Stein Gold will discuss topical management in an in-depth seminar.

Considering the whole patient is crucial in understanding how natural alternatives can improve the skin.

Lauren Miller, MPAS, and Tj Chao, MPAS, discuss how patient goals and education can inform next steps of treatment for plaque psoriasis (PP).

Experts offer insights on treatment selection and patient education for plaque psoriasis (PP).

Dawn L. Sammons, DO, FAOCD, FAAD, and Benjamin Lockshin, MD, FAAD, review a case of a female patient with a family history of plaque psoriasis.

Experts discuss the unique mechanism of action of tapinarof and its use in the treatment of plaque psoriasis.

The IL-23p19 inhibitor demonstrated long-term efficacy and safety.

Researchers examined the disease while going beyond current diagnostic tools.

Lauren Miller, MPAS, and Tj Chao, MPAS, offer considerations for treating pediatric patients with plaque psoriasis (PP).

Experts discuss plaque psoriasis (PP) treatment options for people who are or may become pregnant.

James Q. Del Rosso, DO, and Dawn L. Sammons, DO, FAOCD, FAAD, review the efficacy of a new topical agent in the treatment of plaque psoriasis, tapinarof, highlighting the remittive data.

Experts in dermatology discuss newer topical treatments, such as tapinarof, in the management of plaque psoriasis.

In patients with high levels of VEGF-A and more severe psoriasis, downregulation of blood vessel area is more abrupt.

Nicholas Brownstone, MD, comments on how newer treatments in plaque psoriasis can impact residency training.

Dawn L. Sammons, DO, FAOCD, FAAD, shares her approach to using topical vs systemic therapy in plaque psoriasis, focusing on patient preference as the driving factor for treatment selection.

Tj Chao, MPAS, and Lauren Miller, MPAS, highlight comorbidities that caregivers should consider when treating patients with plaque psoriasis (PP).

Lauren Miller, MPAS, and Tj Chao, MPAS, discuss key factors to consider for plaque psoriasis (PP) treatment.

New research into the disease’s pathogenesis may inform future treatment options.

As many as 1 in 5 patients with psoriasis experience depression as a comorbidity.

A plethora of oral and topical treatments are available for patients, according to Stein Gold’s SCALE 2023 sessions.

Experts discuss the role and importance of physician assistants in the treatment and care of plaque psoriasis (PP).

Tj Chao, MPAS, and Lauren Miller, MPAS, discuss the symptoms of plaque psoriasis (PP) and why it may be difficult to diagnose.

Brad Glick, DO, FAOCD, highlights topical therapy as a targeted treatment of plaque psoriasis.

Benjamin Lockshin, MD, FAAD, comments on how the evolution of the pathophysiology of plaque psoriasis has led to more targeted therapies to treat the disease.

The intention is to expedite the development and review of the drug helping adults with generalized pustular psoriasis.